Medline Subsidiaries Complete $4.75B Debt Refinancing; Private Equity Owners Finalize $2.68B Secondary Offering
MDLN is trading near its 52-week low of $34.34 (4.7% above the low).
Summary
Medline's subsidiaries completed a $4.75 billion debt refinancing while its private equity owners finalized a $2.68 billion secondary stock offering, offloading shares at $37.00 each, a price above the current market value as the stock trades near 52-week lows.
Key Events · Financing and Capital Events · MDLN
-
Debt Refinancing Completed
Medline's indirect subsidiaries issued $1.25 billion in 5.000% senior secured notes due 2031 and $750 million in 5.250% senior secured notes due 2033. Concurrently, they refinanced an existing term loan with a new $2.75 billion senior secured term loan facility due 2033. Proceeds were used to repay existing debt, including a 2028 term loan, $724 million of a 2030 term loan, and $500 million of 6.250% senior secured notes due 2029.
-
Secondary Offering Finalized by Selling Stockholders
Certain selling stockholders, including affiliates of Blackstone Inc., Hellman & Friedman LLC, and Abu Dhabi Investment Authority, completed a previously-announced underwritten public offering of 72,554,594 Class A common shares at $37.00 per share, totaling approximately $2.68 billion. The company itself received no proceeds from this sale.
-
Private Equity Reducing Stake
This offering marks a significant liquidity event for major private equity owners, continuing a trend of reducing their ownership stake in Medline Inc.
-
Stock Performance Post-Offering
The offering price of $37.00 per share is above the current stock price of $35.94, and the stock is trading near its 52-week low, suggesting a decline in market value since the offering was priced and completed on May 28, 2026.
Analysis · MDLN · Industrial Applications And Services
This filing details two major financial events for Medline. Its subsidiaries completed a substantial $4.75 billion debt refinancing, issuing new senior secured notes and a term loan to repay existing debt and extend maturities. This demonstrates the company's continued access to debt capital markets. Concurrently, private equity selling stockholders finalized a large secondary offering, selling 72.55 million Class A common shares for $2.68 billion. This transaction provides no proceeds to Medline and represents a significant reduction in the private equity owners' stake, following a pattern of large sales. The offering price of $37.00 per share is above the current market price of $35.94, with the stock trading near its 52-week low, indicating a decline in value since the offering was priced and completed. This ongoing exit by major shareholders, coupled with the stock's recent performance, creates an overhang and raises concerns about long-term conviction.
How filings like this one have moved
In the 30 days to Sep 22, 2026, 39.7% of the 335 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.40%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDLN was trading at $35.94 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $30.2B. The 52-week trading range was $34.34 to $50.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.